Palbociclib In Real-World Practice Before And During COVID-19 Pandemic - A Single Institute Experience.

Palbociclib is one of three available CDK4/6 inhibitors. This prospective observational study looked at the utilization of Palbociclib in metastatic breast cancer (MBC) during the COVID-19 pandemic period, particularly outlining the disease course and its impact on patients and health services. The rapid spread of the SARS-CoV-2 pandemic and the increased risk of clinically severe diseases in cancer patients were worrying. During this period, it was observed that oral. Palbociclib was tolerated well during the pandemic with minimal toxicity and good response. In the context of the COVID-19 pandemic, Palbociclib is an option for patients with HR+ and HER2-negative advanced breast cancer.